NDA 208246 · Pfizer
Xeljanz Xr
Tofacitinib Citrate · Oral
Last checked: Nov 19, 2026Latest source record: Sep 16, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2016
Feb 23, 2016
Approved uses
7
Original approval plus efficacy supplements
Registered trials
247
52 Phase 3, 36 recruiting
FAERS reports
184,023
88,585 serious, 9,502 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: SERIOUS INFECTIONS, MORTALITY, MALIGNANCY, MAJOR ADVERSE CARDIOVASCULAR EVENTS, and THROMBOSIS WARNING: SERIOUS INFECTIONS, MORTALITY, MALIGNANCY, MAJOR ADVERSE CARDIOVASCULAR EVENTS, and THROMBOSIS See full prescribing information for complete boxed warning. • Increased risk of serious bacterial, fungal, viral, and opportunistic infections, including tuberculosis (TB), leading to hospitalization or death. Interrupt XELJANZ/XELJANZ XR treatment if serious infection occurs until the infection is controlled. Test for latent TB before and during therapy; treat latent TB prior to use. Monitor all patients for active TB during treatment, even patients with initial negative latent TB test. ( 5.1 ) • Higher rate of all-cause mortality, including sudden cardiovascular (CV) death with XELJANZ vs. TNF blockers in rheumatoid arthritis (RA) patients. ( 5.2 ) • Malignancies have occurred in...
What it is approved for
From the label in effect Nov 10, 2026.
XELJANZ (tablets and oral solution) and XELJANZ XR (extended-release tablets) are Janus kinase (JAK) inhibitors. XELJANZ tablets and XELJANZ XR are indicated for the treatment of adult patients with: • Moderately to severely active rheumatoid arthritis (RA), who have had an inadequate response or intolerance to one or more TNF blockers. • Active psoriatic arthritis (PsA), who have had an inadequate response or intolerance to one or more TNF blockers. • Active ankylosing spondylitis (AS), who have had an inadequate response or intolerance to one or more TNF blockers. • Moderately to severely active ulcerative colitis (UC), who have had an inadequate response or intolerance to one or more TNF blockers. XELJANZ (tablets and oral solution) are indicated for the treatment of pediatric patients 2 years of age and older with: • Active PsA, who have had an inadequate response or intolerance to one or more TNF blockers. • Active polyarticular course juvenile idiopathic arthritis (pcJIA), who have had an inadequate response or intolerance to one or more TNF blockers. Limitations of Use : • Use of XELJANZ/XELJANZ XR for RA, AS, PsA, or pcJIA in combination with biologic DMARDs or potent immunosuppressants such as azathioprine and cyclosporine is not recommended. ( 1.1 , 1.2 , 1.3 , 1.4 ) • Use of XELJANZ tablets and XELJANZ XR for UC in combination with biological therapies for UC or with potent immunosuppressants such as azathioprine and cyclosporine is not recommended. ( 1.5 ) 1.1 Rheumatoid Arthritis XELJANZ tablets and XELJANZ XR (extended-release tablets) are indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA), who have had an inadequate response or intolerance to one or more TNF blockers. Limitations of Use Use of...
Mechanism: Tofacitinib is a Janus kinase (JAK) inhibitor. JAKs are intracellular enzymes which transmit signals arising from cytokine or growth factor-receptor interactions on the cellular membrane to influence cellular processes of hematopoiesis and immune cell function. Within the signaling pathway, JAKs phosphorylate and activate Signal Transducers and Activators of Transcription (STATs) which modulate intracellular activity including gene expression. Tofacitinib modulates the signaling pathway at the point of JAKs, preventing the phosphorylation and activation of STATs. JAK enzymes transmit cytokine...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Mar 6, 2026 Supplement 27 · Efficacy LetterLabel
- Feb 21, 2025 Supplement 25 · Efficacy LabelLetter
- Dec 14, 2021 Supplement 13 · Efficacy LabelLetter
- Dec 12, 2019 Supplement 9 · Efficacy LetterLabel
- Dec 14, 2017 Supplement 3 · Efficacy LabelLetter
- Aug 22, 2017 Supplement 1 · Efficacy Label
- Feb 23, 2016 Original approval · Type 3 - New Dosage Form LabelReviewLetter
2 products under this application
- XELJANZ XR · TOFACITINIB CITRATE EQ 11MG BASE · TABLET, EXTENDED RELEASE, ORAL · Prescription · TE AB
- XELJANZ XR · TOFACITINIB CITRATE EQ 22MG BASE · TABLET, EXTENDED RELEASE, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Tofacitinib" as an intervention, any sponsor and status, largest first.
- Long-Term Effectiveness And Safety Of CP-690,550 For The Treatment Of Rheumatoid ArthritisPivotal-lookingCompleted
PfizerPfizer (PFE)
NCT00413699 · 4,488 participants · Start Feb 5, 2007 · Primary completion Nov 30, 2016
Drug: CP-690,550; CP-690,550 · For: Arthritis, Rheumatoid
Sites: Birmingham, Alabama; Huntsville, Alabama; Gilbert, Arizona · 469 sites in all
- Safety Study Of Tofacitinib Versus Tumor Necrosis Factor (TNF) Inhibitor In Subjects With Rheumatoid ArthritisPivotal-lookingCompleted
PfizerPfizer (PFE)
NCT02092467 · 4,372 participants · Start Mar 14, 2014 · Primary completion Jul 22, 2020
Drug: tofacitinib; tofacitinib and 2 more · For: Arthritis, Rheumatoid
Sites: Birmingham, Alabama; Huntsville, Alabama; Tuscaloosa, Alabama · 345 sites in all
- Long-term Safety and Efficacy of GSK3196165 (Otilimab) in the Treatment of Rheumatoid Arthritis (RA)Pivotal-lookingTerminated
GlaxoSmithKlineGSK (GSK)
NCT04333147 · 2,916 participants · Start May 12, 2020 · Primary completion Feb 24, 2023
Drug: Otilimab (GSK3196165); csDMARD(s) · For: Arthritis, Rheumatoid
Sites: Anniston, Alabama; Flagstaff, Arizona; Gilbert, Arizona · 375 sites in all
- A Long Term Study To Evaluate The Safety And Tolerability Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque PsoriasisPivotal-lookingTerminated
PfizerPfizer (PFE)
NCT01163253 · 2,867 participants · Start Sep 2010 · Primary completion Jun 2016
Drug: CP-690,550; CP-690,550 · For: Psoriasis
Sites: Birmingham, Alabama; Mobile, Alabama; Tucson, Arizona · 323 sites in all
GlaxoSmithKlineGSK (GSK)
NCT03970837 · 1,764 participants · Start Jun 5, 2019 · Primary completion Oct 29, 2021
Drug: GSK3196165 (Otilimab); Tofacitinib and 1 more · For: Arthritis, Rheumatoid
Sites: Flagstaff, Arizona; Glendale, Arizona; Mesa, Arizona · 269 sites in all
- Efficacy and Safety of GSK3196165 Versus Placebo and Tofacitinib in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to MethotrexatePivotal-lookingCompleted
GlaxoSmithKlineGSK (GSK)
NCT03980483 · 1,537 participants · Start May 16, 2019 · Primary completion Sep 15, 2021
Drug: GSK3196165 (Otilimab); Tofacitinib 5 mg and 2 more · For: Arthritis, Rheumatoid
Sites: Bengbu, China; Pingxiang, China; Changchun, China · 76 sites in all
- An Efficacy And Safety Study Evaluating Tofacitinib With And Without Methotrexate Compared To Adalimumab With MethotrexatePivotal-lookingCompleted
PfizerPfizer (PFE)
NCT02187055 · 1,152 participants · Start Aug 2014 · Primary completion Dec 2016
Drug: Tofacitinib with methotrexate; Tofacitinib without methotrexate and 1 more · For: Rhematoid Arthritis
Sites: Huntsville, Alabama; Gilbert, Arizona; Covina, California · 215 sites in all
- A Phase 3, Multi Site, Randomized, Double Blind, Placebo Controlled Study Of The Efficacy And Safety Comparing CP- 690,550 And Etanercept In Subjects With Moderate To Severe Chronic Plaque PsoriasisPivotal-lookingCompleted
PfizerPfizer (PFE)
NCT01241591 · 1,101 participants · Start Nov 2010 · Primary completion Jan 2013
Drug: CP 690,550 5 mg; CP 690,550 10 mg and 1 more · For: Psoriasis
Sites: Buenos Aires, Argentina; Feldkirch, Austria; Innsbruck, Austria · 122 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective43,969
- pain26,135
- arthralgia20,062
- condition aggravated19,789
- rheumatoid arthritis19,208
- fatigue16,945
- off label use15,236
- joint swelling14,808
- headache13,701
- rash12,289
- drug intolerance12,020
- malaise10,773
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2008 | 1 |
| 2009 | 1 |
| 2011 | 2 |
| 2012 | 30 |
| 2013 | 1,743 |
| 2014 | 2,735 |
| 2015 | 4,604 |
| 2016 | 9,473 |
| 2017 | 15,399 |
| 2018 | 20,836 |
| 2019 | 22,021 |
| 2020 | 27,376 |
| 2021 | 19,223 |
| 2022 | 24,837 |
| 2023 | 14,046 |
| 2024 | 11,500 |
| 2025 | 8,234 |
| 2026 | 1,962 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Xeljanz XR (Tofacitinib Citrate)
2024 spending
$590M
Beneficiaries
12,581
94,342 claims
Per beneficiary
$46,880
$190.71 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $575,315,148 |
| 2021 | $625,705,276 |
| 2022 | $591,107,821 |
| 2023 | $585,772,572 |
| 2024 | $589,794,983 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis.
Ytterberg SR, Bhatt DL, Mikuls TR, et al. · N Engl J Med 2022 · Comparative Study, Equivalence Trial
- Comparative Efficacy of Advanced Therapies for Management of Moderate-to-Severe Ulcerative Colitis: 2024 American Gastroenterological Association Evidence Synthesis.
Ananthakrishnan AN, Murad MH, Scott FI, et al. · Gastroenterology 2024 · Systematic Review, Comparative Study
- Comparative efficacy of biologics and oral agents in palmoplantar psoriasis and palmoplantar pustulosis: A systematic review and network meta-analysis of randomized clinical trials.
Spencer RK, Jin JQ, Elhage KG, et al. · J Am Acad Dermatol 2023 · Letter, Network Meta-Analysis
- Ulcerative Colitis-Diagnostic and Therapeutic Algorithms.
Kucharzik T, Koletzko S, Kannengiesser K, et al. · Dtsch Arztebl Int 2020 · Meta-Analysis, Review
- Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis.
Sandborn WJ, Su C, Sands BE, et al. · N Engl J Med 2017 · Clinical Trial, Phase III, Multicenter Study
- Tofacitinib in Acute Severe Ulcerative Colitis (TACOS): A Randomized Controlled Trial.
Singh A, Goyal MK, Midha V, et al. · Am J Gastroenterol 2024 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
Sponsor: Pfizer
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.